Advances in immunotherapy for non-small cell lung cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 205-208, 2018.
Artigo
em Chinês
| WPRIM
| ID: wpr-706780
ABSTRACT
The theory of tumor immunity has gone through more than a century of exploration and shown remarkable clinical efficacy. Therapy based on targeting immune checkpoints,especially anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibody monotherapy,has made significant progress in the treatment of advanced lung cancer.Consequently,the discovery of new immune checkpoints has be-come an area of interest.Additionally,combined immunotherapy is expected to be the future direction of immunotherapy.However, at this stage,immunotherapy has not yet resulted in widespread benefit.Identifying immune resistance mechanisms will further pro-mote individualized treatment.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Clinical Oncology
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS